Back

Programmable Drug Control of Receptor Valency Modulates the Potency of Cell Therapeutics

Finn, P.; Chavez, M.; Chen, X.; Wang, H.; Rane, D. A.; Gurjar, J.; Qi, L. S.

2023-01-04 synthetic biology
10.1101/2023.01.04.522664 bioRxiv
Show abstract

Designer T cells offer a novel paradigm for treating diseases like cancer, yet they are often hindered by target recognition evasion and limited in vivo control. To overcome these challenges, we develop valency-controlled receptors (VCRs), a novel class of synthetic receptors engineered to enable precise modulation of immune cell activity. VCRs use custom-designed valency-control ligands (VCLs) to modulate T cell signaling via spatial molecular clustering. Using multivalent DNA origami as VCL, we first establish that valency is important for tuning the activity of CD3-mediated immune activation. We then generate multivalent formats of clinically relevant drugs as VCL and incorporate VCR into the architecture of chimeric antigen receptors (CARs). Our data demonstrate that VCL-mediated VCRs can significantly amplify CAR activities and improve suboptimal CARs. Finally, through medicinal chemistry, we synthesize programmable, bioavailable VCL drugs that potentiate targeted immune response against low-antigen tumors both in vitro and in vivo. Our findings establish receptor valency as a core mechanism for enhancing CAR functionality and offer a synthetic chemical biology platform for strengthening customizable, potent, and safer cell therapies.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
Nature Communications
○ 5641 papers in training set
Top 10%
18.1%
Similar papers in this journal
2
Nature Biotechnology
○ 172 papers in training set
Top 0.5%
6.6%
Similar papers in this journal
3
Nature Biomedical Engineering
○ 47 papers in training set
Top 0.1%
6.6%
Similar papers in this journal
4
Science Advances
● 1243 papers in training set
Top 3%
6.6%
Similar papers in this journal
5
Nature Chemical Biology
○ 119 papers in training set
Top 0.3%
6.1%
Similar papers in this journal
6
Cell
○ 431 papers in training set
Top 1%
5.4%
7
ACS Synthetic Biology
● 287 papers in training set
Top 0.7%
4.7%
50% of probability mass above
8
Proceedings of the National Academy of Sciences
● 2444 papers in training set
Top 11%
4.7%
9
Nature Nanotechnology
○ 32 papers in training set
Top 0.1%
4.4%
10
ACS Nano
● 113 papers in training set
Top 0.7%
3.2%
11
Cancer Cell
○ 42 papers in training set
Top 0.4%
3.2%
12
ACS Central Science
● 71 papers in training set
Top 0.4%
2.6%
13
Science Translational Medicine
● 127 papers in training set
Top 1%
2.3%
14
Journal of the American Chemical Society
● 217 papers in training set
Top 2%
2.1%
15
Cell Chemical Biology
○ 94 papers in training set
Top 0.6%
2.1%
16
Molecular Therapy Oncology
○ 10 papers in training set
Top 0.1%
1.7%
17
Science
● 477 papers in training set
Top 6%
1.5%
18
ACS Chemical Biology
● 167 papers in training set
Top 2%
1.4%
19
eLife
● 5828 papers in training set
Top 60%
1.1%
20
Molecular Therapy
○ 81 papers in training set
Top 1%
1.0%
21
Angewandte Chemie International Edition
○ 93 papers in training set
Top 2%
1.0%
22
Bioconjugate Chemistry
● 20 papers in training set
Top 0.3%
1.0%
23
Cell Reports Medicine
○ 153 papers in training set
Top 5%
0.8%
24
Advanced Science
○ 286 papers in training set
Top 10%
0.8%
25
Advanced Materials
○ 56 papers in training set
Top 1%
0.8%
26
Nucleic Acids Research
◐ 1281 papers in training set
Top 14%
0.8%
27
Nature
○ 645 papers in training set
Top 11%
0.8%
28
Immunity
○ 67 papers in training set
Top 2%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.